1. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (20th October 2022) Authors: Concin, Nicole; Monk, Bradley J; Mirza, Mansoor Raza; Coleman, Robert L; Ray-Coquard, Isabelle; Pothuri, Bhavana; Baurain, Jean-Francois; Alejandro Perez-Fidalgo, J; Cibula, David; Saverse, Antonella; Banerjee, Susana; Madry, Radek; Marth, Christian; Putiri, Emily; Barrett, Jamie; DeMars, Leslie;... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (4th December 2022) Authors: Richardson, Debra; Perez Fidalgo, Jose Alejandro; Gonzalez-Martin, Antonio; Oaknin, Ana; Hamilton, Erika; Hays, John; Pothuri, Bhavana; Papadopoulos, Kyriakos; Taylor, Sara; Huang, Marilyn; Lee, Yeh-Chen; Krivak, Thomas; Moreno-Garcia, Victor; Calvo, Emiliano; Randall, Leslie; Starks, David; Ross... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗